top of page
Research Area
I am currently working with Dr. Vaishali Kilor as a research team. Our primary objective is to develop healthcare products that address unmet medical needs. Our work mainly focus on identifying potential therapeutic agents, either alone or in combination, and utilizing modern technologies to overcome any limitations associated with them.
Soothoral Gel
Canker sores, which are small and painful lesions inside the mouth, make eating, drinking, and speaking uncomfortable. Although they are usually harmless, they can recur frequently and cause significant discomfort. Our oral gel, consisting of a unique blend of herbal ingredients, has been proven effective in pre-clinical studies for treating mouth ulcers/aphthous stomatitis Clinical studies are ongoing, and the trademark is being registered with a patent application filed.
This product is available for out-licensing to interested clients.
Soothoral-OM
Oral mucositis caused by chemotherapy is a serious condition that results painful mouth sores, making it difficult to eat, drink, and speak. It has a significant impact on quality of life, increases the risk of infection, and may require a reduction or delay in cancer treatment. Unfortunately, there are currently no effective treatments available.
We have identified a unique combination of ingredients that has shown impressive efficacy in the animal model. We are developing suitable formulation that is convenient for application in such patients.
The product is being developed considering the regulatory requirements of major markets.
Memorizer
Alzheimer's disease is a complex and debilitating neurodegenerative disorder that poses a significant global health challenge. With an estimated 50 million people affected worldwide, and indicating a tripling of this number by 2050, the need for effective treatments is more pressing than ever. While no cure currently exists, we are leveraging modern scientific techniques and traditional knowledge to develop an effective product for this disease.
The product has shown promising results in the initial preclinical studies. This multicomponent product is now at an advanced stage of development. Regulatory requirements are carefully considered at every stage of the development process.
Veinasin
Hesperidin is a citrus bioflavonoid known for its activity in venous diseases like varicose veins and hemorrhoids. We have developed an enhanced version of hesperidin that have shown greater activity in animal model of hemorrhoids than the micronized purified flavonoid fraction (MPFF) in 9:1 ratio. We are developing hesperidin tablets with greater bioavailability. The product composition is as per regulatory requirements and the physical attributes are convenient to patients. We are taking due care to keep the manufacturing processes simple and easily scalable.
Mediprint-DR
Printing of medicines is a very recent area and very little work has been done in that. We developed “printing of medicines on thin-films” technology from the scratch. Our project was supported by research grant from DST-SERB, Government of India and Zim Laboratories limited. We transferred this technology to Zim Lab. Now we have developed delayed release technique where we can print drugs with delayed release profile on the film substrate. In this the film substrate dissolves quickly while the printed design is ingested intact that releases the drug as a function of pH. This technique finds its application for pediatric, geriatric and dysphagic patients. All the low dose drugs requiring delayed release profile can be developed using this technique.
We undertake projects to develop products as per clients’ specific requirements.
Jawease
Oral submucous fibrosis (OSMF) is a chronic, precancerous condition predominantly found in South Asia, particularly in India, Pakistan, Sri Lanka, and Southeast Asia. The global prevalence of OSMF varies but is estimated to be around 2.5 million people. Among betel nut chewers, prevalence can reach up to 6%. There is no treatment for this disease.
We are developing a formulation using the ingredients that are selected through in-sillico and in-vitro studies. This is a novel formulation especially designed for such patients where the major problem is difficulty in opening of mouth.
bottom of page